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Abstract The death of macrophages contributes to atheroma
formation. Oxidation renders low-density lipoprotein (LDL)
cytotoxic to human monocyte-macrophages. Lipoprotein-asso-
ciated phospholipase A2 (Lp-PLA2), also termed platelet-acti-
vating factor acetylhydrolase, hydrolyses oxidised phospholipids.
Inhibition of Lp-PLA2 by diisopropyl fluorophosphate or
Pefabloc (broad-spectrum serine esterase/protease inhibitors),
or SB222657 (a specific inhibitor of Lp-PLA2) did not prevent
LDL oxidation, but diminished the ensuing toxicity and
apoptosis induction when the LDL was oxidised, and inhibited
the rise in lysophosphatidylcholine levels that occurred in the
inhibitors’ absence. Hydrolysis products of oxidised phospholip-
ids thus account for over a third of the cytotoxic and apoptosis-
inducing effects of oxidised LDL on macrophages. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Amongst the evidence implicating low-density lipoprotein
(LDL) oxidation in atherosclerosis progression is that oxi-
dised LDL (oxLDL) has toxic and apoptosis-inducing e¡ects
on macrophages and smooth muscle cells (SMCs) [1^5]. Some
of these cells die, by apoptosis and necrosis, in advanced
atherosclerotic lesions [6,7]. Death of macrophage foam cells
leads to lipid spillage and development of the lipid core (athe-
roma) of advanced plaques [8], whilst death of SMCs attenu-
ates the ¢brous cap. Such changes destabilise lesions, predis-
posing them to rupture, leading to thrombosis [9^11].
OxLDL contains a complex, incompletely characterised
mixture of toxic oxidation products, including oxysterols, lip-
id hydroperoxides and their breakdown products, e.g. 4-hy-
droxynon-2-enal (HNE) [12^15]. Also produced are the core
aldehydes, of unknown toxicity, in which an unsaturated fatty
acid chain (originally usually 18 or 20 carbons) has become
peroxidised and oxidatively fragmented (typically to nine or
¢ve carbons, terminating in an aldehyde group) but retains its
ester link to the parent lipid. Phosphatidylcholine (PC)-de-
rived core aldehydes (PCCAs) were ¢rst described as oxida-
tively fragmented PCs [16]. PCCAs and cholesterol ester-de-
rived core aldehydes (CECAs) occur in Cu2-oxLDL [17,18].
CECAs were found in LDL oxidised by J774 macrophage-like
murine cells [19] and in human atherosclerotic lesions [20,21].
Oxidised PCs, including PCCAs, have platelet-activating
factor (PAF)-like pro-in£ammatory activity [22,23] and are
mitogenic for SMCs [23]. PCCAs are substrates for lipopro-
tein-associated phospholipase A2 (Lp-PLA2), an enzyme asso-
ciated with LDL, also known as platelet-activating factor ace-
tylhydrolase (PAF-AH). Lp-PLA2 hydrolyses PCCAs to
lysophosphatidylcholine (lyso-PC), whilst non-oxidised PCs
are insusceptible [16,24].
We therefore investigated the role of LDL-associated Lp-
PLA2 in the cytotoxicity and apoptosis-inducing e¡ects of
oxLDL for human monocyte-macrophages (HMMs) in vitro.
2. Materials and methods
Pefabloc (4-(2-aminoethyl)-benzenesulphonyl £uoride) and the lac-
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tate dehydrogenase (LDH) release assay kit were from Roche (Lewes,
UK). Diisopropyl £uorophosphate (DFP) was from Aldrich (Gilling-
ham, UK). SB222657 was a gift of Glaxo SmithKline (Harlow, UK).
The nucleosome enzyme-linked immunosorbent assay (ELISA) kit
was from Oncogene (CN Biosciences, Nottingham, UK). Other chem-
icals, culture plates and media were as described previously [3].
The isolation of human monocytes from blood (normal volunteers)
or bu¡y coat (National Blood Service), HMM culture (in Macro-
phage-SFM serum-free medium), LDL preparation, HMM-mediated
LDL oxidation (in Ham’s F-10 medium supplemented with 3 WM
Fe2SO4, 10.8 mg/l phenol red and 2 mM glutamine), measurement
of relative electrophoretic mobility (REM) and of thiobarbituric acid-
reactive substances (TBARS) was as described previously [1,3,25,26].
Measurement by gas chromatography (GC) of free plus esteri¢ed in-
dividual fatty acids and 7L-hydroxycholesterol (7L-HC) in LDL and
oxLDL was as before [3]. HMMs were cultured in Macrophage-SFM
for 1^2 days prior to starting experiments.
1-Palmitoyl-2-(9-oxononanoyl)-sn-glycero-3-phosphocholine (PC-9-
oxo) was synthesised by bubbling ozone from a Pennwalt ozone gen-
erator (100^140 V; 50 ml/min) through a solution of 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (100 mg; Sigma) in dichlorome-
thane (DCM; 40 ml) at 370‡C for c. 1 h until it turned blue (excess
ozone) indicating completion. Excess ozone was purged out (3 min)
using oxygen; dimethylsulphide (DMS, 0.5 ml) was added (370‡C;
1 h), and then allowed to warm to room temperature. DCM and
DMS were removed by rotary evaporation, then by a vacuum line.
PC-9-oxo was puri¢ed by column chromatography on alumina
(Brockman grade II^III), eluting with an increasing gradient of meth-
anol in chloroform. The principle of ozonolysis was employed previ-
ously for PCCA synthesis [16,27,28]. CECAs were synthesised from
cholesterol esters using osmium tetroxide by the method of Kamido et
al. [36] and by our ozonolysis procedure (similar but not identical to
that above). Molar yields of aldehydes synthesised by ozonolysis were
c. 50%. Products were characterised by 1H NMR (600 MHz), fast
atom bombardment mass spectrometry, thin layer chromatography
(TLC) and reversed-phase high pressure liquid chromatography
(HPLC).
Liposomes were made by injecting solutions (40^100 mM; in etha-
nol) of PC-9-oxo, or non-oxidised PC (1-palmitoyl-2-oleoyl-sn-glyc-
ero-3-phosphocholine), or lyso-PC (1-hexadecanoyl-sn-glycero-3-phos-
phocholine; Sigma) through a ¢ne needle into rapidly stirred
incubation medium (Macrophage-SFM) at 37‡C to give the desired
¢nal concentrations [29]. The ethanol vehicle (not exceeding 1% v/v)
was non-toxic to the HMM cultures.
To irreversibly inhibit Lp-PLA2, LDL (3 mg LDL protein/ml) was
pretreated for 5 h at 37‡C with 10 mM DFP [30] using isopropanol
(IPA; 0.5% v/v) as the solvent vehicle. Excess DFP and IPA vehicle
were then removed by dialysis (overnight with three bu¡er changes)
against phosphate-bu¡ered saline (PBS). Control LDL was prepared
in parallel, omitting the DFP but with IPA and all other conditions
identical. Pefabloc [31,40] and SB222657 [32] were also used to inhibit
Lp-PLA2. LDL (1 mg LDL protein/ml) was pretreated with 500 WM
Pefabloc (water-soluble) or 2 WM SB222657 (vehicle dimethylsulph-
oxide (DMSO); 0.5% v/v) for 30 min at 37‡C; control LDL (no
inhibitor) was maintained in parallel. The LDLs were diluted to
1 mg LDL protein/ml in PBS, and were oxidised by exposure to
copper sulphate (10 WM) for 15 h at 37‡C. Cu2 was removed by
Chelex-100 resin [26], and the oxLDLs were added to HMM cultures
in Macrophage-SFM at 200 Wg LDL protein/ml. The ¢nal concentra-
tions of Pefabloc or SB222657 were 100 WM or 0.4 WM, respectively.
Incubations were up to 54 h. Toxicity was assessed by [3H]adenine
release (HMMs preloaded with [3H]adenine; 0.25 WCi per well) [1] and
by LDH release. Apoptosis was measured by nucleosome ELISA.
Pefabloc and SB222657 (no LDL) were themselves non-toxic to
HMMs at the ¢nal concentrations used. The DMSO vehicle used as
above was non-toxic to HMMs and did not a¡ect LDL oxidation.
SB222657 (no LDL) gave background levels of apoptosis similar to no
additions HMMs. DFP (10 mM) employed as above inhibited 97% of
the native LDL-associated Lp-PLA2 activity, using a published meth-
od to measure the hydrolysis of [3H]PAF (NEN, Boston, MA, USA)
to [3H]lyso-PAF [33]. Cu2-mediated oxidation of LDL (DFP-pre-
treated and its control as above) was also performed at 0.2 mg
LDL protein/ml in PBS using 5 WM Cu2 for up to 72 h at 37‡C,
then stopped using EDTA (1.6 mM) and butylated hydroxytoluene
(32 WM) and stored at 320‡C until analysis.
For HMM-mediated LDL oxidation, native LDL was pretreated
with DFP as above. Pretreatment of native LDL with Pefabloc (500
WM) was at 2 mg LDL protein/ml in PBS containing 27 WM EDTA,
for 30 min at 37‡C. Pretreatment of native LDL with SB222657
(2 WM) was at 200 Wg LDL protein/ml for 30 min at 37‡C in Ham’s
F-10 medium. The pretreated native LDLs were then added (individ-
ually) to HMM cultures in Ham’s F-10 medium to give ¢nal concen-
trations of 200 Wg LDL protein/ml. Toxicity was monitored for up to
72 h by the [3H]adenine release method [3].
For aldehyde analysis, 4 ml of oxLDL (200 Wg LDL protein/ml
oxidised by 5 WM Cu2 or by HMMs) were mixed with 4 ml 2,4-
dinitrophenylhydrazine solution (1.77 mM in 1 M HCl), to form the
2,4-dinitrophenylhydrazone (DNPH) derivatives of the aldehydes
[34,35]. After 2 h in the dark at room temperature, the aldehyde-
DNPH derivatives were extracted [35] and separated on silica gel
TLC plates [35], eluted as described [18]. Bands were scraped and
extracted, using DCM for hexanal and CECAs, DCM/methanol
(2:1, v/v) for HNE, and DCM/methanol (1:1, v/v) for PCCAs. The
extracts were evaporated under a stream of nitrogen, redissolved in
methanol and injected onto a reversed-phase column (Spherisorb
ODS2, 4.6 mmU25 cm; Waters; 40‡C) on a Hewlett Packard 1050
HPLC. The mobile phase for PCCAs was isocratic methanol/water/
acetonitrile 93:7:5 (v/v/v) containing 20 mM choline chloride [16],
1 ml/min, detected at 378 nm. Mobile phases and detection wave-
lengths for HNE and CECAs were as described previously [18,35];
those for hexanal were as for HNE. Components were identi¢ed by
retention times and quanti¢ed by peak areas (using a Hewlett Packard
ChemStation data system), compared with standards.
For analysis of lyso-PC and PC, samples of LDL and oxLDL
(0.5 ml of 1 mg LDL protein/ml), to which an internal standard,
1,2-dipentadecanoyl-sn-glycero-3-phosphocholine (Sigma), was added
(100 Wl of a 1 mg/ml solution), were extracted by the Bligh and Dyer
method and a phospholipid fraction isolated by the method of
Kaluszny et al. [37] using aminopropyl Sep-pak cartridges (Millipore)
on a Waters 24 position manifold. The phospholipids were dried
down under N2 and redissolved in diethyl ether (1 ml), then hydro-
lysed and analysed by our adaptation of published procedures [38], as
follows. Phospholipase C (10^20 U/mg protein, type I from Clostri-
dium welchii ; Sigma P 7633) was dissolved at 5 mg/ml in bu¡er
(50 mM Tris, 30 mM CaCl2, pH 7.3) and 20 Wl diluted with a further
1 ml of the same bu¡er. It was preextracted with 2U1 ml washes of
diethyl ether (to remove lipid impurities), and then mixed with 1 ml of
phospholipid solution (prepared above) and stirred overnight at room
temperature. The diethyl ether layer, containing the liberated mono-
and diacylglycerols (M/DAGs), was then collected, and pooled with a
further 2U2 ml diethyl ether extracts of the aqueous phase, then dried
under N2. The M/DAGs were treated with bistrimethylsilyltri£uoro-
acetamide plus 1% trimethylchlorosilane (Pierce) to form trimethylsi-
lylether (TMSi-ether) derivatives. Excess reagents were evaporated o¡
under N2. The M/DAG TMSi-ether derivatives were then dissolved in
hexane (0.5 ml) and 1 Wl analysed by GC (Carlo Erba GC8000).
Injection was via a cold on-column injector onto a 30 m DB-1 column
[3], temperature programmed 50^200‡C at 10‡C/min, 200^300‡C at
4‡C/min, and then held at 300‡C for 20 min. The carrier gas was
hydrogen and detection was by a £ame ionisation detector. Quantita-
tion was by peak areas measured by a Shimadzu CR3A integrator,
relative to the internal standard.
Mean values of data are þ S.D. Where error bars are not visible in
graphs, the S.D. is smaller than the relevant data point symbol. Sta-
tistical analysis was by Student’s t-test (unpaired). Experiments were
repeated several times and representative data are presented.
3. Results and discussion
All three inhibitors of Lp-PLA2 ^ DFP, Pefabloc and
SB222657 ^ resulted in diminished toxicity, determined by
the [3H]adenine release assay, when the inhibitor-pretreated
LDL was subsequently oxidised by Cu2 and then added to
HMMs (Fig. 1a). The results for Pefabloc and SB222657 were
con¢rmed by the LDH release assay (Fig. 1b). OxLDL-in-
duced apoptosis in HMMs, measured by nucleosome ELISA,
was similarly diminished by SB222657 (Fig. 1c).
Lyso-PC levels in control Cu2-oxLDL averaged 4.3-fold
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higher than those of native LDL, but in those which had been
pretreated with inhibitors of Lp-PLA2 prior to oxidation (in-
hibitor-pretreated oxLDL, IN-oxLDL) lyso-PC only rose to
1.2^1.5-fold higher than native LDL (Fig. 2a). Inhibition of
lyso-PC production was thus 85% or greater. PC loss as a
result of oxidation was c. 40% regardless of inhibition of
Lp-PLA2 (Fig. 2b). Levels of PC cannot drop below c. 50%
of native levels because the remainder possess saturated or
mono-unsaturated chains that resist peroxidation [39]. The
REMs of IN-oxLDL for all three inhibitors and control
oxLDL were about equal (Fig. 2c). Loss of total free plus
esteri¢ed linoleate was 59^67% and that of arachidonate was
86^92%, as a result of oxidation, regardless of inhibition of
Lp-PLA2 for all three inhibitors. 7L-HC was negligible in
native LDL, whilst in IN-oxLDL (DFP-pretreated) and its
corresponding control oxLDL 7L-HC levels were 30.6 and
25.3 Wg/mg LDL protein, respectively. In IN-oxLDL (Pefa-
bloc- or SB222657-pretreated) and control oxLDL, 7L-HC
levels were 14.4, 11.3 and 12.9 Wg/mg LDL protein, respec-
tively. Levels of TBARS (nmol malondialdehyde/mg LDL
protein) were not signi¢cantly di¡erent (Ps 0.1) for control
oxLDL (40.6 þ 6.4, n = 5) and IN-oxLDL (for Pefabloc,
43.6 þ 14.0, n = 5; for SB222657 45.0 þ 8.2, n = 5). Thus the
diminished toxicity of IN-oxLDL relative to control oxLDL
was not due to inhibition of oxidation per se.
Pretreatment of native LDL individually with DFP, Pefa-
bloc or SB222657 conferred a variable degree of protection
against the self-in£icted toxicity arising from HMM-mediated
LDL oxidation, within the oxidising cultures themselves (in
Ham’s F-10 medium). This protection was only apparent in
the later stages (s 24 h) and ranged from c. 30% inhibition
with DFP to over 80% with SB222657 or Pefabloc.
PCCAs were undetectable in native LDL. After oxidation
by Cu2 for 20 h and 48 h, PCCA levels in IN-oxLDL (DFP-
pretreated) were 6.8 and 10.4 nmol/mg LDL protein, respec-
tively, whereas in corresponding control oxLDL they were 3.5
and 4.9 nmol/mg LDL protein. Corresponding REMs were
3.2 and 4.8 for IN-oxLDL and 3.0 and 4.7 for control
oxLDL. Throughout a time course (0, 6, 12, 24, 48 and 72
h) production of HNE, hexanal and CECAs was similar in
IN-oxLDL (DFP-pretreated) and control oxLDL. For exam-
ple, hexanal levels peaked at 24 h, with 84.6 and 85.3 nmol/mg
LDL protein for IN-oxLDL and control oxLDL, respectively.
HNE also peaked at 24 h, with 27.5 and 26.1 nmol/mg LDL
protein. Cholesteryl 9-oxononanoate peaked at 12 h, with 29.8
and 30.8 nmol/mg LDL protein. Cholesteryl 5-oxovalerate
peaked at 6 h, with 6.0 and 6.3 nmol/mg LDL protein.
For HMM-mediated oxidation of LDL in Ham’s F-10 me-
dium, after 24, 48 and 72 h PCCA levels in IN-oxLDL (DFP-
pretreated) were 7.2, 8.4 and 15.5 nmol/mg LDL protein,
whilst for corresponding control oxLDL they were 0.9, 5.7
and 7.1 nmol/mg LDL protein. The corresponding REMs
Fig. 1. Cytotoxicity to HMMs of Cu2-oxLDL, with or without
pretreatment with inhibitors of Lp-PLA2 prior to the oxidation.
LDL was oxidised at 1 mg protein/ml in PBS, using 10 WM Cu2
for 15 h at 37‡C, then incubated with HMMs in Macrophage-SFM
at 200 Wg LDL protein/ml culture medium. For further details see
Section 2. (a) Toxicity was measured by the [3H]adenine release
method. Data points are means of three to six replicate wells þ S.D.
S, control oxLDL, no inhibitor; F, control oxLDL, sham-pre-
treated with solvent vehicle as a control for DFP ((3)DFP-oxLDL);
E, DFP (10 mM)-pretreated, oxLDL ((+)DFP-oxLDL); O, Pefa-
bloc (500 WM)-pretreated oxLDL (PFB-oxLDL); P, SB222657
(2 WM)-pretreated oxLDL (SB-oxLDL); a, no additions control (no
adds), i.e. HMMs cultured in medium alone. Toxicity of inhibitor-
pretreated oxLDL was signi¢cantly di¡erent from that of control
oxLDL that had not been pretreated, or in the case of DFP, from
that of control oxLDL that had been sham-pretreated with solvent
vehicle, as follows: at 24 h and 54 h, for SB222657 P6 0.01 and
P6 0.0001, respectively; for Pefabloc P6 0.05 and P6 0.001; for
DFP P6 0.01 and P6 0.001. (b) Toxicity was measured by the
LDH release method. Data points are means of triplicate
wells þ S.D. Treatments and symbols are as in panel a except that
DFP was not assessed. Toxicity of inhibitor-pretreated oxLDL was
signi¢cantly di¡erent from that of control oxLDL, at 24 h and 48 h,
respectively, for SB222657 P6 0.01 and P6 0.001; for Pefabloc
P6 0.01 and P6 0.0001. (c) Apoptosis of HMMs was measured by
nucleosome ELISA. Treatment was as in panel a for SB222657.
DFP and Pefabloc were not assessed. Gliotoxin (5 WM) was a posi-
tive control for apoptosis. Calcium ionophore A23187 (100 WM;
0.5 h), a necrosis-inducing agent, was a negative control for apopto-
sis. Data are means of triplicate wells þ S.D. Apoptosis induced by
SB-oxLDL was signi¢cantly di¡erent from that of control oxLDL,
at 24 h and 48 h, respectively, P6 0.01 and P6 0.001.
C
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were 1.8, 2.6, and 3.0 for IN-oxLDL and 1.8, 2.4 and 2.9 for
control oxLDL. CECAs were also detected in HMM-oxLDL,
but the e¡ect of inhibitors of Lp-PLA2 on their production
was not measured.
To assess the toxicities of lyso-PC and PCCAs, we added
them individually (as liposomes) at a range of concentrations
to cultures of HMMs in Macrophage-SFM. For lyso-PC, a
sharp increase in toxicity was seen between 50 and 100 WM,
and maximal toxicity was reached at 150 WM (Fig. 3a). By
comparison the dose-related increase in toxicity of PC-9-oxo
was gradual (Fig. 3b). Levels of lyso-PC in oxLDL, when
translated into ¢nal concentrations in the culture medium,
were 24^40 WM, i.e. slightly under the toxic threshold concen-
tration for pure lyso-PC. Hydrolysis of oxidised PC theoret-
ically yields 1 mol of oxidised non-esteri¢ed fatty acid (oxNE-
FA) per mol of lyso-PC liberated, so oxNEFA (presumably
including aldehydic acids) might contribute to the toxicity.
The combined e¡ect of lyso-PC and oxNEFA with other cy-
totoxins in oxLDL, e.g. oxysterols, lipid hydroperoxides, and
aldehydes such as HNE, may be important. PCCA levels in
oxLDL corresponded to only a few WM ¢nal concentration in
the medium, i.e. well below the toxic threshold concentration
for synthetic PCCAs. Local concentrations of lyso-PC, oxNE-
FA or PCCAs within oxLDL particles would be higher than
bulk concentrations in the medium, and this might a¡ect tox-
icity.
The reduction in toxicity caused by the Lp-PLA2 inhibitors
is unlikely to be due to prevention of uptake of oxLDL by
HMMs, as pretreatment of native LDL with DFP or
SB222657 did not inhibit subsequent uptake by mouse peri-
toneal macrophages or J774 cells respectively, following oxi-
dation by Cu2 or mouse peritoneal macrophages ([30]; D.S.
Leake and S.E. Stait, unpublished observations).
PCCA production during LDL oxidation only represents a
few per cent of the loss of PC on a molar basis, even when
Lp-PLA2 is inhibited. Moreover, production of lyso-PC in
control oxLDL is c. 30% (on a molar basis) of the loss of
PC, suggesting that not all oxidised PC is hydrolysed, possibly
because of rapid binding of oxidised PC (including PCCAs) to
apolipoprotein B-100. Also PCCAs and lyso-PC might be
further converted to other products not detectable by our
assays. Exogenously added PCCAs bind covalently to pro-
teins and peptides [41,42]. PCCAs and PCCA-modi¢ed pro-
tein are recognised by macrophages, and are epitopes involved
Fig. 3. Cytotoxicity to HMMs of (a) lyso-PC and (b) PC-9-oxo,
measured by the [3H]adenine release method. Incubations were for
24 h in Macrophage-SFM. Data points are means of triplicate
wells þ S.D. *P6 0.01, **P6 0.001, toxicity signi¢cantly di¡erent
(a) for lyso-PC compared with control (no lyso-PC) and (b) for PC-
9-oxo compared with non-oxidised PC.
Fig. 2. E¡ect of inhibitors of Lp-PLA2 on (a) levels of lyso-PC, (b)
levels of PC and (c) REM for Cu2-oxLDL. Results are mean val-
ues ( þ S.D.) for native (nat) LDL (n = 6), and for oxLDL (n = 5),
SB-oxLDL (n = 4), PFB-oxLDL (n = 4), (3)DFP-oxLDL (n = 4) and
(+)DFP-oxLDL (n = 4), expressed relative to the corresponding na-
tive LDL in each case; n = number of experiments. Lyso-PC levels
for SB-oxLDL, PFB-oxLDL and (+)DFP-oxLDL were signi¢cantly
di¡erent (P6 0.03) from those of oxLDL. Lyso-PC levels in
(3)DFP-oxLDL were not signi¢cantly di¡erent from those of
oxLDL (Ps 0.1). PC levels and REM for SB-oxLDL, PFB-oxLDL,
(+)DFP-oxLDL and (3)DFP-oxLDL were not signi¢cantly di¡erent
from those of oxLDL (Ps 0.1). Abbreviations and oxidation condi-
tions are as in Fig. 1.
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in the antigenicity of oxLDL [28,43^45]. Lp-PLA2 may be
able to hydrolyse oxidised fatty acid chains in the sn-2 posi-
tion of PC before they fragment into aldehydes [32], possibly
explaining the low observed PCCA levels in control
oxLDL.
The role of Lp-PLA2 is vexed. Both lyso-PC and oxida-
tively fragmented phospholipids (including PCCAs) are mito-
genic for SMCs [23,48] and appear involved in the antigenicity
of oxLDL [28,43^45,49]. Oxidatively fragmented phospholip-
ids possess pro-in£ammatory, PAF-like activity [22,23], and as
shown here, are cytotoxic to HMMs, albeit less so than lyso-
PC. Lyso-PC is a chemoattractant for monocytes [47]. Lyso-
PC is a detergent, and can, under some conditions, kill cells
by disrupting the plasma membrane [50]. Lyso-PC can induce
apoptosis in endothelial cells and SMCs in vitro [50,51], so
might similarly a¡ect macrophages. The oxNEFA fraction
arising from Lp-PLA2-mediated hydrolysis of oxLDL is a
chemoattractant for monocytes, and pretreatment of LDL
with SB222657 before oxidation inhibited this [32].
Plasma Lp-PLA2 activity is predominantly associated with
LDL, and a smaller proportion with high-density lipoprotein
(HDL) [52^54]. HDL-associated Lp-PLA2 may have a protec-
tive role in atherosclerosis [46,55]. The Lp-PLA2 of LDL is
predominantly associated with a small, dense atherogenic
LDL sub-fraction [56]. Plasma Lp-PLA2 activity appears par-
tially heritable [57]. Lp-PLA2 de¢ciency in plasma, due to a
missense mutation, was a risk factor for ischaemic heart dis-
ease in Japanese men [58], but the overall signi¢cance of this
mutation remains complex and unclear [59]. De¢ciency in Lp-
PLA2 activity was reported in LDL from patients with fam-
ilial hypercholesterolaemia [33]. Others have reported elevated
plasma Lp-PLA2 activity in patients with familial hypercho-
lesterolaemia [60] and arterial disease [54,61,62]. Moreover,
elevated levels of plasma Lp-PLA2 were a strong independent
predictor of coronary artery disease [63]. Lp-PLA2 distribu-
tion between LDL and HDL, and LDL-associated Lp-PLA2
activity in combination with oxidisability of LDL (in£uenced
by dietary polyunsaturated fatty acids and antioxidants, e.g.
vitamin E), might be important determinants of risk. Also the
potentially relevant roles of intracellular and cell-secreted Lp-
PLA2/PAF-AH in tissues are little understood [64]. The tox-
icity of PC-9-oxo to HMMs in vitro (Fig. 3b) might arise at
least partly from hydrolysis to lyso-PC and oxNEFA by Lp-
PLA2 secreted by the cells. In vitro, mature macrophages and,
to a lesser degree, freshly isolated monocytes secrete Lp-PLA2
identical to LDL-associated Lp-PLA2 [65^67]. Lp-PLA2
mRNA and protein occur in macrophages in human and rab-
bit atherosclerotic lesions [67].
The reduction in oxLDL-mediated death of HMMs, as a
result of inhibition of Lp-PLA2, was due at least partly to
diminution of apoptosis, as judged by nucleosome ELISA.
Supporting evidence from £ow cytometry of propidium io-
dide-stained HMMs (following treatment with ethanol and
RNase), using a published method [68], showed that 15% of
total cells were hypodiploid (in a pattern typical of apoptotic
cells) for uninhibited, oxLDL-treated HMMs (24 h), which
decreased to 12% for IN-oxLDL (SB222657-pretreated), com-
pared with a background of 3% in no additions control
HMMs. Fluorescence microscopy of HMMs treated and
stained as above revealed nuclear abnormalities characteristic
of apoptosis (chromatin condensation or nuclear fragmenta-
tion) in c. 50%, 30% and 7% of the HMMs, respectively.
Although the details of the execution mechanism(s) are out-
side the scope of the present study, some important consid-
erations follow. Internucleosomal cleavage of DNA has long
been considered a hallmark of apoptosis [69,70] and is due to
activation of caspase-activated DNase (CAD) as a result of
caspase-mediated cleavage of its inhibitor, ICAD. Caspase
activation (especially the executioner caspase 3) plays a piv-
otal role in apoptosis and caspase 3 activation was detected in
Cu2-oxLDL-induced apoptosis in HMMs [68]. In human
atherosclerotic lesions, colocalisation of CPP-32 (caspase 3)
with TUNEL-positive cells (predominantly macrophages) sug-
gests a role for caspase activation in apoptosis in atheroscler-
otic plaques in vivo [71], although both necrosis and apoptosis
appear to occur in atherosclerotic plaques [7]. Classical apo-
ptosis and necrosis have been suggested to represent the ends
of a continuum of modes of death, with varying contributions
of the cellular machinery [72]. Caspase-independent cell sui-
cide can occur with certain combinations of cell types and
stimuli, and other proteases may take over some of the roles
of caspases [72]. Moreover, inhibiting caspase activation can
reveal or even enhance caspase-independent cell death [72]. It
was suggested that in atherosclerotic lesions macrophage ne-
crosis might be promoted if their caspases are inactivated [7].
LDL oxidised by Cu2 to a degree [26] similar to that used in
the present study produced classical apoptotic nuclear ultra-
structural changes in HMMs [1]. The e¡ect of Lp-PLA2 inhi-
bition on caspase activation in oxLDL-treated HMMs is thus
a potentially complex issue that merits investigation in its own
right.
The role of Lp-PLA2 in atherosclerosis is still incompletely
understood. In this study, inhibition of Lp-PLA2 typically
diminished between a third and a half of the ensuing toxicity
and apoptosis-inducing e¡ect of the LDL when subsequently
oxidised. The products of Lp-PLA2-mediated hydrolysis of
oxidised PC thus appear to account for a substantial propor-
tion of the death of human macrophages. These ¢ndings may
be relevant to the death of macrophage foam cells and SMCs
in atherosclerotic lesions and progression of lesions to a state
vulnerable to rupture.
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